Dr. Christopher Twelves on the Rising Issue of Metastatic Breast Cancer
Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed.
Christopher Twelves, MD, professor of Clinical Cancer Pharmacology and Oncology at the Leeds Institute of Cancer and Pathology, St James's Institute of Oncology, Leeds, UK, discusses the rising issue of metastatic breast cancer.
Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed. He adds that while this is not only untrue, the issue of metastatic breast cancer will become more and more of an issue as the years go on.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
